SG11201700060WA - Methods of improving myocardial performance in fontan patients using udenafil compositions - Google Patents

Methods of improving myocardial performance in fontan patients using udenafil compositions

Info

Publication number
SG11201700060WA
SG11201700060WA SG11201700060WA SG11201700060WA SG11201700060WA SG 11201700060W A SG11201700060W A SG 11201700060WA SG 11201700060W A SG11201700060W A SG 11201700060WA SG 11201700060W A SG11201700060W A SG 11201700060WA SG 11201700060W A SG11201700060W A SG 11201700060WA
Authority
SG
Singapore
Prior art keywords
methods
myocardial performance
improving myocardial
fontan patients
udenafil
Prior art date
Application number
SG11201700060WA
Other languages
English (en)
Inventor
James L Yeager
Original Assignee
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd filed Critical Mezzion Pharma Co Ltd
Publication of SG11201700060WA publication Critical patent/SG11201700060WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201700060WA 2014-08-12 2015-06-30 Methods of improving myocardial performance in fontan patients using udenafil compositions SG11201700060WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036506P 2014-08-12 2014-08-12
US201562186132P 2015-06-29 2015-06-29
PCT/US2015/038638 WO2016025100A2 (fr) 2014-08-12 2015-06-30 Procédés d'amélioration de la performance du myocarde chez des patients opérés d'un fontan, au moyen de compositions d'udénafil

Publications (1)

Publication Number Publication Date
SG11201700060WA true SG11201700060WA (en) 2017-02-27

Family

ID=55301323

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700060WA SG11201700060WA (en) 2014-08-12 2015-06-30 Methods of improving myocardial performance in fontan patients using udenafil compositions
SG10202100300RA SG10202100300RA (en) 2014-08-12 2015-06-30 Methods of Improving Myocardial Performance in Fontan Patients Using Udenafil Compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202100300RA SG10202100300RA (en) 2014-08-12 2015-06-30 Methods of Improving Myocardial Performance in Fontan Patients Using Udenafil Compositions

Country Status (24)

Country Link
US (6) US10137128B2 (fr)
EP (2) EP3180008B1 (fr)
JP (4) JP2017524705A (fr)
KR (3) KR20170066334A (fr)
CN (1) CN107073001A (fr)
AU (3) AU2015302271B2 (fr)
BR (1) BR112017002675A2 (fr)
CA (5) CA3128705A1 (fr)
CL (1) CL2017000329A1 (fr)
CO (1) CO2017000271A2 (fr)
DO (1) DOP2017000014A (fr)
EA (1) EA201692518A3 (fr)
EC (1) ECSP17015154A (fr)
IL (2) IL285193B2 (fr)
MX (1) MX2017001396A (fr)
MY (1) MY200278A (fr)
NZ (2) NZ765796A (fr)
PE (1) PE20170469A1 (fr)
PH (1) PH12017500120A1 (fr)
SG (2) SG11201700060WA (fr)
TN (1) TN2017000029A1 (fr)
TW (5) TWI730944B (fr)
UA (1) UA120514C2 (fr)
WO (1) WO2016025100A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201692518A3 (ru) 2014-08-12 2017-11-30 Меццион Фарма Ко., Лтд. Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
US20170112858A1 (en) * 2015-10-27 2017-04-27 New Haven Pharmaceuticals, Inc. Extended Release Aspirin
KR102249155B1 (ko) 2019-07-26 2021-05-07 주식회사 코아팜바이오 유데나필을 함유하는 약제학적 조성물
JP2022550734A (ja) * 2019-09-24 2022-12-05 メジオン ファーマ カンパニー リミテッド ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数(mpi)を改善する方法
CA3229274A1 (fr) 2021-08-13 2023-02-16 Mezzion Pharma Co., Ltd. Methodes et compositions permettant de traiter des affections hepatiques fibrotiques, a l'aide de compositions d'udenafil
WO2023121689A1 (fr) 2021-12-20 2023-06-29 Mezzion Pharma Co., Ltd. Méthodes et compositions pour améliorer les performances d'exercice

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US20050272741A1 (en) * 2004-01-16 2005-12-08 Jack Rychik Novel methods of treatment for Fontan patients with protein losing enteropathy
EP1931797A2 (fr) 2005-09-29 2008-06-18 Bayer HealthCare AG Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
KR100792126B1 (ko) 2006-04-04 2008-01-04 동아제약주식회사 피라졸로피리미디논 화합물을 유효성분으로 함유하는전립선 비대증 예방 및 치료제
KR101002490B1 (ko) 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
KR20100029762A (ko) 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 pde 억제제
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101071877B1 (ko) * 2009-02-18 2011-10-10 동아제약주식회사 유데나필 산부가염, 그의 제조방법 및 이를 포함하는 약학적 조성물
DK2512479T3 (en) 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
JP5883687B2 (ja) 2011-03-09 2016-03-15 第一三共ヘルスケア株式会社 Pde5阻害剤含有医薬組成物
KR101383430B1 (ko) 2012-01-26 2014-04-08 광동제약 주식회사 새로운 조합의 구강내 속붕해 필름형성 조성물 및 pde5 저해제가 함유된 구강내 속붕해 필름제제
MX2015006023A (es) 2012-11-13 2016-03-31 Nusirt Sciences Inc Composiciones y metodos para incrementar el metabolismo energetico.
EA201692518A3 (ru) 2014-08-12 2017-11-30 Меццион Фарма Ко., Лтд. Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила

Also Published As

Publication number Publication date
TW202118491A (zh) 2021-05-16
IL250547B (en) 2021-07-29
TW202002982A (zh) 2020-01-16
IL250547A0 (en) 2017-03-30
US20160045510A1 (en) 2016-02-18
CA3128697A1 (fr) 2016-02-18
US10653698B2 (en) 2020-05-19
KR20170066334A (ko) 2017-06-14
PE20170469A1 (es) 2017-04-21
CL2017000329A1 (es) 2017-11-03
CN107073001A (zh) 2017-08-18
US20230095034A1 (en) 2023-03-30
JP2024020187A (ja) 2024-02-14
EA201692518A2 (ru) 2017-07-31
US20180169103A1 (en) 2018-06-21
AU2021202212A1 (en) 2021-05-06
EA201692518A3 (ru) 2017-11-30
CA3128705A1 (fr) 2016-02-18
TWI730944B (zh) 2021-06-21
US20220047601A1 (en) 2022-02-17
US20190030038A1 (en) 2019-01-31
CA3128680A1 (fr) 2016-02-18
NZ765800A (en) 2024-03-22
CA2954183A1 (fr) 2016-02-18
TN2017000029A1 (en) 2018-07-04
EP3180008B1 (fr) 2023-11-29
TWI767153B (zh) 2022-06-11
TW202400176A (zh) 2024-01-01
IL285193B2 (en) 2023-11-01
JP2019077726A (ja) 2019-05-23
WO2016025100A2 (fr) 2016-02-18
JP2021091721A (ja) 2021-06-17
EP4342531A2 (fr) 2024-03-27
UA120514C2 (uk) 2019-12-26
NZ765796A (en) 2024-02-23
SG10202100300RA (en) 2021-02-25
IL285193A (en) 2021-08-31
EP3180008A4 (fr) 2018-01-24
ECSP17015154A (es) 2017-05-31
TW201617080A (zh) 2016-05-16
KR20230116098A (ko) 2023-08-03
CA2954183C (fr) 2023-10-31
AU2015302271B2 (en) 2019-02-28
DOP2017000014A (es) 2017-06-30
EP4342531A3 (fr) 2024-06-26
MX2017001396A (es) 2017-12-04
JP2017524705A (ja) 2017-08-31
KR20210038708A (ko) 2021-04-07
TW202224685A (zh) 2022-07-01
AU2019203706A1 (en) 2019-06-20
IL285193B1 (en) 2023-07-01
US10137128B2 (en) 2018-11-27
US20190030037A1 (en) 2019-01-31
AU2015302271A1 (en) 2017-01-12
CA3128691A1 (fr) 2016-02-18
EP3180008A2 (fr) 2017-06-21
BR112017002675A2 (pt) 2017-12-12
PH12017500120A1 (en) 2017-05-29
CO2017000271A2 (es) 2017-05-31
MY200278A (en) 2023-12-18

Similar Documents

Publication Publication Date Title
HK1258041A1 (zh) 免疫細胞組合物和使用方法
HRP20192145T1 (hr) Pripravci nosača-antitijela i metode pripreme i uporabe istih
HK1254525A1 (zh) 治療組合物、組合和使用方法
IL249011B (en) Methods and preparations related to exosomes
GB2535253B (en) Compositions and methods
IL285193A (en) Methods to improve myocardial function in Fontan surgery patients using iodenafil compounds
GB2535423B (en) Cementing compositions and methods
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
GB201417828D0 (en) New methods and compositions
SG11201609254YA (en) Therapeutic placental compositions, methods of making and methods of use
HK1243334A1 (zh) 刺激和擴大t細胞的組合物和方法
IL248160A0 (en) Compositions of tissue fillers and methods of use
HK1255221A1 (zh) 使用卡多曲組合物進行治療的方法
HK1246653A1 (zh) 奧那司酮延長釋放組合物和方法
PT3148517T (pt) Composições e métodos para promover a formação óssea
PL3223846T3 (pl) Kompozycje adiuwantowe i powiązane sposoby
HK1243404A1 (zh) 色酰胺組合物和使用方法
IL251345B (en) Preparations for use in the treatment of peri-implantitis
GB201408233D0 (en) Use of polyanionic composition
GB201402915D0 (en) Compositions and methods
GB201621390D0 (en) Novel compositions having use in therapy
GB201404391D0 (en) Novel compositions having use in therapy
GB201502816D0 (en) Novel Compositions having use in therapy
GB201600570D0 (en) Novel compositions having use in therapy
GB201419559D0 (en) Therapeutic compositions and methods